Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14763815 | 0.77 | CES2 (0.46) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL6881837 | 0.77 | CES2 (0.46) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL15823364 | 0.76 | EPHX1 (0.37) | CES2CES1SMN1; SMN2HTTEPHX1 | |
| SCHEMBL2900646 | 0.76 | CES2 (0.33) | CES2CES1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL63153 | 0.76 | CES2 (0.44) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL1441061 | 0.76 | CES2 (0.44) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL15442771 | 0.76 | CES2 (0.44) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL106920 | 0.76 | CES2 (0.44) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL15442922 | 0.76 | CES2 (0.44) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL15443495 | 0.76 | CES2 (0.44) | CES2CES1SMN1; SMN2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5597943-A | Phospholipase A2 inhibitor | SHIONOGI & CO., LTD. (JP) | 1997-01-28 | — | — | US | claimed |
| US-5268386-A | Containing a carboxy group | SHIONOGI & CO., LTD. (JP) | 1993-12-07 | — | — | US | claimed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | claimed |
| US-9937157-B2 | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2582812-B1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20160317505-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9248119-B2 | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9107912-B2 | Methods for concomitant treatment of theophylline and febuxostat | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2613780-B1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS USA INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140329868-A1 | METHODS FOR TREATING HYPERTENSION | TAKEDA PHARMACEUTICALS USA INC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-5214037-A | Antibiotic, bactericide | SHIONOGI & CO., LTD. (JP) | 1993-05-25 | — | — | US | disclosed |
| EP-0528678-A1 | A pyrrolidylthiocarbapenem derivative | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| EP-0348203-B1 | PHENOLIC THIOETHERS, THEIR PRODUCTION AND USE | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1993-02-24 | — | — | EP | disclosed |
| EP-0521524-A1 | Aminooxypyrrolidinylthiocarbapenem compounds | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1993-01-07 | — | — | EP | disclosed |
| US-5084214-A | Compounds for the treatment of artheriosclerosis | SHIONOGI & CO., LTD. (JP) | 1992-01-28 | — | — | US | disclosed |
| EP-0467647-A2 | Thioalkylthio cephalosporin derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-5064954-A | Phosphorylation of hydroxymethylcarbapem and halogenation; bactericides | SHIONOGI & CO., LTD. (JP) | 1991-11-12 | — | — | US | disclosed |
| EP-0415566-A1 | Heterocyclic compounds, processes for producing them and pharmaceutical compositions comprising them | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317505-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | XDH, PNPO, DUOX1 | CES2 349/4885CES1 325/4885SMN1; SMN2 1806/4885 |
| US-20140329868-A1 | METHODS FOR TREATING HYPERTENSION | XDH, REN, CYP11B2 | CES2 160/4885CES1 467/4885SMN1; SMN2 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.